Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Wednesday, March 27, 2019

#Biotech Stock News: Positive Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)


#Biotech Stock News: Positive Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)


Point Roberts, WA, Delta BC - March 27, 2019 - Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance.

GELifesciences.com, talking about the Antibody boom says; “Many small and start-up companies are developing new ideas as to how antibodies can be used. In many cases, these companies will go on to be acquired by larger companies with the financial capability to progress their ideas further. But with costs to establish manufacturing capability in suitable existing buildings at not much more than $10-15 M, this strategic opportunity lies within reach even for smaller businesses. Despite steep competition and the need for significant investment, the antibody space is a lucrative opportunity with various therapeutic avenues that can be explored.”

Looking at some companies in the sector, Immunoprecise Antibodies Ltd. (TSXV: IPA) (OTC: IPATF), a therapeutic antibody discovery company, recently received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc., which currently operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute (NCI). Under the subcontract, IPA will discover and produce rabbit monoclonal antibodies using its proprietary B-Cell Select platform.

The rabbit monoclonal antibodies discovered and produced under this subcontract will be used in the key applications of immunohistochemistry and immuno-Multiple Reaction Monitoring (immuno-MRM). The antibodies will be generated for NCI’s Antibody Characterization Program.

Immuno-MRM is a leading-edge targeted mass spectrometry technique that relies on antibodies to enrich peptides from complex biological samples that are then quantified by mass spectrometry. Rabbit monoclonal antibodies are highly sought after for this purpose because they exhibit high specificity and bind their target with high affinity. Immuno-MRM is being used to discover novel biomarkers and develop a new generation of clinical diagnostic tests that could lead to improved cancer detection, diagnosis, and treatment.


Zymeworks Inc. (NYSE: ZYME) (TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics reported in January the achievement of a new development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly’s submission of an IND application for an immuno-oncology bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform.
Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of cancer recently reported positive preliminary efficacy data for the primary endpoint of its ongoing Phase 3 registration trial, the VISTA Trial, of Vicinium® for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-GuĂ©rin (BCG) and deemed BCG-unresponsive. The data reported show clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and twelve months of follow-up in the trial consistent with the data in the completed Phase 1 and Phase 2 clinical trials. Importantly, Vicinium continues to be generally well-tolerated in treated patients.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTC: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases will soon present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease.  ProMIS Neurosciences' Chief Scientific Officer, Dr. Neil Cashman will discuss the preclinical data at a podium presentation on March 31 as well as co-moderate the March 30 panel discussion on disease mechanisms in Alzheimer's disease and Parkinson's disease.

ResearchandMarkets, in a biopharma market overview reported, “The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%.”

Within the related segments, Monoclonal Antibodies are expected to gain the largest market size.

For investors following medical technology and healthcare stocks, Investor Ideas has created a directory of biotech and medical technology stocks

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI

Follow us on Social Media
Follow us on Twitter https://twitter.com/Investorideas


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article featuring  (TSX VENTURE: IPA) (OTC PINK: IPATF)  a paid for service on Investorideas.com(third party)  . Learn more about costs and our  services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411

Friday, March 22, 2019

Investor Ideas Adds Recent #Nasdaq IPO Stocks- Biotech, China-Asia and Energy Sectors – ($KLDO), ( $INMB), ( $SXTC), ( $MDJH) ( $MTC), ( $NFE)

Investor Ideas Adds Recent #Nasdaq IPO Stocks- Biotech, China-Asia and Energy Sectors – ($KLDO), ( $INMB), ( $SXTC), ( $MDJH)
( $MTC), ( $NFE) 



Point Roberts, WA, Delta BC – March 22, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in biotech, China-Asia and energy.

Investorideas.com is a go-to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members.


All new additions this week are recent Nasdaq IPO’s and include biotech, energy, and China-based companies.

New biotech stocks are clinical stage biotechnology companies involved in treatments using microbiomes and the innate immune system, respectively.

The latest China stocks include a cross-over into the life sciences sector of our biotech stocks directory, a fintech company and a real estate services company.

The newest energy company is involved in the natural gas infrastructure sector.

New Biotech Companies
Kaleido Biosciences, Inc. (NasdaqGS:KLDO) is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

INmune BIO, INC. (NasdaqCM:INMB) is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation

New China/Asia Companies
CHINA SXT PHARMACEUTICALS, INC. (NasdaqCM:SXTC) is an innovative pharmaceutical company based in China focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine tablets (the “TCMP”).

MMTEC, INC. (NasdaqCM::MTC) is a technology company in providing access to the US markets on an omnibus and DVP basis. The core business of MMTEC, INC. is to provide comprehensive, Internet-based technology services and solutions to the China local hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. We help these financial institutions to accelerate their integration into the overseas market by offering complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction and settlement.

MDJM LTD (NasdaqCM:MDJH) is an emerging, integrated real estate services company in China. The Company offers primary real estate agency services to real estate developers including integrated marketing planning, advertising planning and strategy. The Company also provides real estate consulting services and independent training services on an as needed basis. Currently, the Company’s primary market is the Tianjin Autonomous Municipality and since 2014 the Company has expanded its market presence to other cities including Chengdu, Suzhou, and Yangzhou. Through two major development businesses, Xishe and Xishe Xianglin, coupled with existing core business, MDJM promotes the integration of urban and rural lifestyle services.

New Energy Companies:
NEW FORTRESS ENERGY LLC (NasdaqGS: NFE) is a global energy infrastructure company founded to help accelerate the world’s transition to clean energy. The company funds, builds and operates natural gas infrastructure and logistics to rapidly deliver fully integrated, turnkey energy solutions that enable economic growth, enhance environmental stewardship and transform local industries and communities. New Fortress Energy is majority-owned by a fund managed by an affiliate of Fortress Investment Group

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411












Friday, March 1, 2019

Investor Ideas Adds New Stocks in #Lithium & Mining and Biotech

Investor Ideas Adds New Stocks in #Lithium & Mining and Biotech (ASX: $AJM.AX, $INF.AX $GLN.AX) (Shenzen:002466.SZ)


Point Roberts, WA, Delta BC – March 1, 2019 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in lithium & mining and biotech.

Investorideas.com is a go-to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members.


All but one of the newest mining companies are involved in lithium mining with the majority listed on the Australian Stock Exchange (ASX) and one listed on the Shenzhen Exchange of China. The non-lithium company is the CSE-listed 21C Metals Inc. (CSE:BULL), which is operating a copper/cobalt operation in Europe.

The latest biotech stocks are all listed on US Exchanges (NYSE/Nasdaq) and are involved in the medical technology aspect of healthcare.

New Lithium & Mining Companies:
Altura Mining Limited (ASX: AJM.AX) is a key player in the global lithium market and is leveraging increasing demand for raw materials for manufacturing lithium ion batteries for electric vehicles and static storage uses. Altura owns and operates the world-class Altura Lithium Project at Pilgangoora in WA’s Pilbara, which has a production capacity of 220,000tpa of quality spodumene concentrate. The Company has completed a Definitive Feasibility Study on a potential Stage 2 expansion to 440,000tpa, with a Final Investment Decision due following a review of the Stage 1 operations and ramp-up to nameplate production.

Tianqi Lithium Corporation (Shenzen:002466.SZ) is a leading new energy materials company in China and globally with lithium at our core. Our businesses include mining and producing of lithium concentrate and manufacturing of lithium compounds. We have established mineral operations, manufacturing plants and subsidiaries in China (Sichuan, Chongqing, Jiangsu) and Australia, allowing the company to serve customers across the globe. 

Infinity Lithium Corporation Limited (ASX:INF.AX) is an Australian listed minerals company and, in partnership with Valoriza Mineria, is seeking to develop the San Jose Lithium Project and produce battery grade lithium hydroxide.  Supply response is needed to satisfy Europe’s burgeoning energy storage needs through feeding the large-scale battery plants currently under construction. The San Jose deposit is a highly advanced, previously mined brownfields development opportunity representing one of Europe’s largest lithium deposits.  Infinity Lithium will mine the hard rock Mica resource and develop processing facilities to provide what would currently be the sole European mine-to-end-product lithium hydroxide operation.

Galan Lithium Limited (ASX:GLN.AX) is an Australian based mineral exploration company established to generate shareholder wealth by identifying, acquiring and/or developing mineral projects. The Company’s projects are located within the South American Lithium Triangle in the Hombre Muerto Basin, one of the most important and prolific salt flats in Argentina and indeed the world. The basin is known to have the lowest impurity levels of any producing Salar in Argentina and has been in production for over 20 years.

21C Metals Inc. (CSE:BULL) (formerly Declan Cobalt) is an independent mineral exploration company based in Vancouver, B.C which is currently pursuing Copper-Cobalt exploration on their projects in Europe.








Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/






New Biotech Companies:
Nuvectra Corporation (NASDAQ: NVTR) is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease

Boston Scientific Corporation (NYSE: BSX) transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

iRhythm Technologies, Inc. (NASDAQ: IRTC) is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

To sponsor a daily podcast for the month or to be an expert guest please contact us!

Contact Investorideas.com
800-665-0411